Is WAY a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Waystar Holding (WAY) rests on AI-driven revenue cycle automation: Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. The bear case rests on concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Analysts covering it publish targets from $28.00 to $44.00 against a $27.36 price, so even the professionals disagree by 47% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix. The investment picture is one of a scaled, sticky software business that turned the corner on GAAP profitability after its 2024 IPO. Revenue grew about 22% year over year in Q1 2026 (roughly 11% organic, the rest from the Iodine Software acquisition) and about 18% in Q2 2026 to roughly $320 million, with adjusted EPS of $0.43 against a $0.40 consensus; net revenue retention sat near 111% earlier in the year, and adjusted EBITDA margins run in the low-40s percent. Trailing revenue is now about $1.21 billion and trailing net income about $135 million. The debate is less about whether the business works and more about valuation: at about 39 times trailing GAAP earnings (but under 15 times 2027 adjusted EPS estimates) and a ~$5.25 billion market cap, roughly 4.3 times trailing revenue, the stock already embeds expectations for sustained growth, successful acquisition integration, and further margin gains. The stock fell hard in the first half of 2026, hitting a 52-week low near $17.26, then rebounded after the strong second quarter and after Reuters reported on September 15 that Waystar was exploring options, including a potential sale, with Evercore advising. The talks were described as early stage, and Barclays downgraded the stock to equal weight the next day.

The bull case: what would have to be true for $44.00

The most optimistic published target on WAY is $44.00, +60.8% from the $27.36 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. AI-driven revenue cycle automation

Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. Because medical billing is labor-intensive and error-prone, automation that lifts clean-claim rates and recovers denials is a concrete efficiency pitch to providers. This is the clearest lever the company points to for both new-logo wins and expansion within existing accounts.

2. Land-and-expand with high retention

Net revenue retention of about 111% means existing customers spend more each year as they adopt additional modules across the platform. With provider solutions growing organically at roughly double the pace of patient-payment solutions, cross-selling more of the suite into an already-large installed base is a durable growth engine. High switching costs in mission-critical billing systems reinforce the stickiness.

3. Iodine acquisition and platform breadth

The Iodine Software acquisition extended Waystar into mid-cycle and clinical-integrity capabilities, and management has said the integration is running ahead of schedule. Bolting complementary capabilities onto one platform lets Waystar sell a broader footprint to the same providers. Continued M&A and cross-sell of acquired capabilities are central to the growth story.

4. Structural demand for billing efficiency

US healthcare billing is famously complex, and providers face persistent margin pressure that makes faster, cleaner collections valuable. The addressable market for RCM software and transactions is often estimated in the $15-20 billion range annually. As a scaled independent platform, Waystar is positioned to consolidate share as providers move off fragmented legacy tools.

5. A possible sale process

On September 15, 2026 Reuters, citing people familiar with the matter, reported that Waystar was exploring strategic options including a sale and had hired Evercore as adviser; the shares rose more than 8% that day. The process was described as early stage, no buyer or price was reported, and the company had not announced any agreement as of October 16, 2026. Until there is a signed deal, the stock still trades on its operating results, but takeover speculation now sits in the price and could reverse if no transaction emerges.

The bear case: what would have to be true for $28.00

The most pessimistic published target is $28.00, +2.3% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Waystar Holding is worth if the risks below bite instead of the drivers above.

Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a trailing P/E near 39 leaves little room for a growth or margin stumble, and the stock remains well below its 52-week high of about $40.35 even after a ~27% three-month rebound. Part of that rebound followed reports of a possible sale, so a process that ends without a deal could take some of it back. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history (about $1.48 billion against roughly $194 million of cash as of mid-2026). Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding WAY already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on WAY

22 analysts cover WAY, with an average target of $34.00 (+24.3% against $27.36) and a split of 21 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the WAY forecast and price target page.

How is WAY valued? (as of October 2026)

Price

$27.36

Market cap

$5.25B

P/E (TTM)

39.09

Forward P/E

14.56

Price / book

1.32

Beta

0.18

52-week range

$17.26 to $40.35

Snapshot for WAY as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$1.21B (+18% YoY in Q2 2026)
Q2 2026 adj. EPS: $0.43 vs $0.40 est.
Net income (TTM): ~$135M (~11% net margin)
P/E (trailing / forward): ~39x / ~14.6x
Market cap: ~$5.25B
2026 revenue guidance (spring): ~$1.274B to $1.294B (consensus ~$1.29B)
Next earnings: Nov 2, 2026 (EPS est. ~$0.41, revenue ~$323M)

Waystar closed at about $27.38 on October 16, 2026, up from around $24 in early July and from a 52-week low near $17.26, but still down roughly 26% from a year earlier. Q2 2026 revenue rose ~18% year over year to ~$320 million and adjusted EPS of $0.43 beat the $0.40 estimate. The trailing GAAP P/E near 39 and a market cap of about 4.3 times trailing revenue reflect expectations for continued double-digit growth and margin expansion, while the forward multiple of about 14.6 times 2027 adjusted EPS looks lower because adjusted figures exclude amortization and stock compensation; since mid-September the price also includes some takeover speculation.

How do you decide if WAY is a buy?

Rather than asking whether WAY is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold WAY indirectly through an index or sector ETF before adding more.

What would change your mind on WAY

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: AI-driven revenue cycle automation stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the WAY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about WAY against your real portfolio and see your actual exposure before deciding.

Investing in Waystar Holding with AI

Connect the broker you already use and ask Walnut's AI how WAY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does WAY fit me?

FAQ

Is WAY a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on AI-driven revenue cycle automation, with revenue (ttm) at ~$1.21B (+18% YoY in Q2 2026). The bear case rests on concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Analysts covering it are spread from $28.00 to $44.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell WAY?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $28.00, +2.3% from the $27.36 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for WAY?

AI-driven revenue cycle automation. Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. The most optimistic analyst target on WAY is $44.00, +60.8% from the $27.36 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for WAY?

What does Waystar Holding do?

Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denial

What would have to change for WAY to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AI-driven revenue cycle automation) stalling in the reported numbers rather than in the narrative, the risk above (concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Waystar (WAY) do?

Waystar provides cloud-based software that healthcare providers use to get paid. Its platform handles eligibility and financial clearance, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics, processing billions of transactions a year across roughly a million providers.

Is Waystar profitable?

Yes. After its 2024 IPO, Waystar turned GAAP-profitable, reporting roughly $135 million in trailing-twelve-month net income as of mid-2026 and adjusted EBITDA margins in the low-40s percent. Q1 2026 net income was about $43 million and Q2 2026 about $41 million.

How fast is Waystar growing?

Revenue grew about 22% year over year in Q1 2026 to roughly $314 million, of which about 11% was organic and the rest came from the Iodine Software acquisition, and about 18% in Q2 2026 to roughly $320 million. Full-year 2026 revenue guidance issued in the spring was roughly $1.274 billion to $1.294 billion, and analyst consensus sits near $1.29 billion.

Walnut is informational, not investment advice, and gives no verdict on WAY. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.